Baqiyatallah Medical Sciences University   Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4
Founded: Tehran Iran (Islamic Republic of) (1994)

Organization Overview

First Clinical Trial
2006
NCT00367419
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Baghiatallah University of Medical Sciences | Baghiatollah | Baqiyatallah Medical Sciences University | Baqiyatallah Research Center for Gastroenterology and Liver Disea | Baqiyatallah University of Medical Sciences | Baqiyatallah University of Medical Sciencesc | Baqiyatallah University of Medical Scienecs | Baqyiattalah University of Medical Science | Mohammad Sadegh Bagheri Baghdasht | Nematollah Jonaidi Jafari | Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University | Research Center of Chemical Injuries, Baqiyatallah Medical Science University, Tehran, Iran | Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Bronchiolitis (Phase 4)

Bronchiolitis Obliterans (Phase 4)

Bronchitis (Phase 3)

Bronchitis, Chronic (Phase 3)

Dyspnea (Phase 3)

Hemophilia A (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis C (Phase 4)

Ileus (Phase 4)

Infarction (Phase 3)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Myocardial Infarction (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Respiratory Aspiration (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Thalassemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 26